Bristol-Myers Squibb will sell its ConvaTec wound care business to a pair of private equity investors for $4.1bn, marking the latest step in the US drugmaker’s effort to sell peripheral assets and focus more on pharmaceuticals.

Europe’s Nordic Capital and US-based fund Avista Capital Partners, which focuses on healthcare, media and energy investments, will unite to turn ConvaTec into a standalone company.